Literature DB >> 18301417

Medical management of lower urinary tract symptoms in men: current treatment and future approaches.

Anand K Patel1, Christopher R Chapple.   

Abstract

Lower urinary tract symptoms (LUTS) are extremely common in men and, in addition to causing considerable bother, can lead to the development of complications, such as acute urinary retention. Over the past couple of decades, developments in the medical management of LUTS in men have led to a substantial decline in the number of surgical procedures being performed to treat associated disorders, such as prostatectomy for benign prostatic enlargement. In this Review we summarize the available treatments and discuss the latest data on the use of anticholinergics and phosphodiesterase type-5 inhibitors for this indication. We also review the various combinations of medical therapies that have been reported in the literature to optimize the management of LUTS in men. In addition, there is a growing realization that LUTS in men are not synonymous with prostatic disease, and in many patients overactive bladder syndrome is the cause or a component of the LUTS experienced; we have, therefore, taken the opportunity to try to clarify the terminology used in LUTS in men, since there is the potential for considerable confusion with the terms that are currently in common usage in any discussion of this disorder.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18301417     DOI: 10.1038/ncpuro1060

Source DB:  PubMed          Journal:  Nat Clin Pract Urol        ISSN: 1743-4270


  6 in total

1.  Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation.

Authors:  P Comeglio; A K Chavalmane; B Fibbi; S Filippi; M Marchetta; M Marini; A Morelli; G Penna; L Vignozzi; G B Vannelli; L Adorini; M Maggi
Journal:  J Endocrinol Invest       Date:  2010-04-12       Impact factor: 4.256

2.  Inhibition of Human Prostate and Bladder Smooth Muscle Contraction, Vasoconstriction of Porcine Renal and Coronary Arteries, and Growth-Related Functions of Prostate Stromal Cells by Presumed Small Molecule Gαq/11 Inhibitor, YM-254890.

Authors:  Alexander Tamalunas; Amin Wendt; Florian Springer; Anna Ciotkowska; Beata Rutz; Ruixiao Wang; Ru Huang; Yuhan Liu; Heiko Schulz; Stephan Ledderose; Giuseppe Magistro; Christian G Stief; Martin Hennenberg
Journal:  Front Physiol       Date:  2022-05-23       Impact factor: 4.755

3.  Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia.

Authors:  K L Lo; M C K Chan; A Wong; S M Hou; C F Ng
Journal:  Int Urol Nephrol       Date:  2009-05-16       Impact factor: 2.370

4.  Influence of Panax ginseng on Alpha-Adrenergic Receptor of Benign Prostatic Hyperplasia.

Authors:  Su Kang Kim; Joo-Ho Chung; Byung-Cheol Lee; Sang Won Lee; Kang Hyo Lee; Young Ock Kim
Journal:  Int Neurourol J       Date:  2014-12-29       Impact factor: 2.835

5.  Inhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model.

Authors:  Su Kang Kim; Hosik Seok; Hae Jeong Park; Hye Sook Jeon; Sang Wook Kang; Byung-Cheol Lee; Jooil Yi; Sang Yeol Song; Sang Hyub Lee; Young Ock Kim; Joo-Ho Chung
Journal:  BMC Complement Altern Med       Date:  2015-10-22       Impact factor: 3.659

6.  The Effect of Xialiqi Capsule on Testosterone-Induced Benign Prostatic Hyperplasia in Rats.

Authors:  Hongcai Cai; Guowei Zhang; Zechen Yan; Xuejun Shang
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-30       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.